Kennen MacKay
Stock Analyst at RBC Capital
(2.20)
# 2,720
Out of 4,761 analysts
39
Total ratings
46.15%
Success rate
7.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kennen MacKay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVB Nuvation Bio | Maintains: Outperform | $4 → $5 | $2.21 | +126.24% | 1 | Apr 17, 2024 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $40 → $42 | $35.22 | +19.25% | 3 | Jun 27, 2023 | |
| AMGN Amgen | Maintains: Sector Perform | $224 → $236 | $303.01 | -22.11% | 4 | Aug 5, 2022 | |
| EXEL Exelixis | Maintains: Outperform | $32 → $31 | $36.85 | -15.88% | 2 | Nov 3, 2021 | |
| ADCT ADC Therapeutics | Maintains: Outperform | $33 → $34 | $1.63 | +1,985.89% | 2 | Nov 3, 2021 | |
| PRTA Prothena Corporation | Maintains: Outperform | $59 → $82 | $15.56 | +426.99% | 5 | Sep 30, 2021 | |
| PBYI Puma Biotechnology | Maintains: Sector Perform | $13 → $6 | $2.91 | +106.54% | 2 | Aug 6, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Sector Perform | $87 → $88 | $68.25 | +28.94% | 9 | Jul 29, 2021 | |
| NRIX Nurix Therapeutics | Initiates: Outperform | $42 | $16.87 | +148.96% | 1 | Apr 30, 2021 | |
| MESO Mesoblast | Initiates: Sector Perform | $48 | $16.37 | +193.22% | 1 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $175 | $5.78 | +2,927.68% | 2 | May 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $18 → $23 | $47.37 | -51.45% | 3 | Apr 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | n/a | $18.59 | - | 3 | Apr 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $0.60 | +2,239.57% | 1 | Sep 15, 2017 |
Nuvation Bio
Apr 17, 2024
Maintains: Outperform
Price Target: $4 → $5
Current: $2.21
Upside: +126.24%
Agios Pharmaceuticals
Jun 27, 2023
Maintains: Outperform
Price Target: $40 → $42
Current: $35.22
Upside: +19.25%
Amgen
Aug 5, 2022
Maintains: Sector Perform
Price Target: $224 → $236
Current: $303.01
Upside: -22.11%
Exelixis
Nov 3, 2021
Maintains: Outperform
Price Target: $32 → $31
Current: $36.85
Upside: -15.88%
ADC Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $33 → $34
Current: $1.63
Upside: +1,985.89%
Prothena Corporation
Sep 30, 2021
Maintains: Outperform
Price Target: $59 → $82
Current: $15.56
Upside: +426.99%
Puma Biotechnology
Aug 6, 2021
Maintains: Sector Perform
Price Target: $13 → $6
Current: $2.91
Upside: +106.54%
BioMarin Pharmaceutical
Jul 29, 2021
Maintains: Sector Perform
Price Target: $87 → $88
Current: $68.25
Upside: +28.94%
Nurix Therapeutics
Apr 30, 2021
Initiates: Outperform
Price Target: $42
Current: $16.87
Upside: +148.96%
Mesoblast
Oct 22, 2020
Initiates: Sector Perform
Price Target: $48
Current: $16.37
Upside: +193.22%
May 8, 2020
Maintains: Outperform
Price Target: $275 → $175
Current: $5.78
Upside: +2,927.68%
Apr 3, 2019
Upgrades: Outperform
Price Target: $18 → $23
Current: $47.37
Upside: -51.45%
Apr 4, 2018
Downgrades: Sector Perform
Price Target: n/a
Current: $18.59
Upside: -
Sep 15, 2017
Initiates: Outperform
Price Target: $14
Current: $0.60
Upside: +2,239.57%